Salient Capital Advisors’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Salient Capital Advisors’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-100,000	Closed	-$135K	–	212
2017 Q2	$135K	Buy	100,000 +40,000	+67%	+$57.8K	﹤0.01%	207
2017 Q1	$128K	Hold	60,000	–	–	﹤0.01%	251
2016 Q4	$265K	Buy	60,000 +10,000	+20%	+$47.5K	0.01%	222
2016 Q3	$243K	Buy	50,000 +40,000	+400%	+$182K	﹤0.01%	222
2016 Q2	$33K	Buy	+10,000	New	+$37.7K	﹤0.01%	244

Other funds holding ARLZ

PCM

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CIM

Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return

BAS

Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

Salient Capital Advisors's ARLZ Position: Q3 2017 in Review

Salient Capital Advisors sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2017, closing a stake of 100,000 shares — an estimated $135K sold.

Salient Capital Advisors first reported a position in ARLZ in Q2 2016 and held it in 5 quarters. The position peaked at $265K in Q4 2016. 59 funds tracked by Wall St. Rank hold ARLZ as of Q3 2017.

Salient Capital Advisors reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2017 after selling out during the quarter.
Salient Capital Advisors sold 100,000 Aralez Pharmaceuticals Inc. shares in Q3 2017, an estimated $135K.
Salient Capital Advisors first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 5 quarters.
Salient Capital Advisors's Aralez Pharmaceuticals Inc. position peaked at $265K in Q4 2016.
59 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2017.

Based on Salient Capital Advisors's 13F filing for Q3 2017, filed 6 Nov 2017.